Professor Paul Nathan is an internationally renowned Consultant Medical Oncologist. His clinical interests include melanoma of the skin, eye, and internal organs; kidney cancer (renal cell carcinoma); and rare skin cancers including Merkel cell carcinoma. Originally trained in cancer immunology, Professor Nathan pursued clinical studies at Cambridge and UCL. He has been a Consultant Medical Oncologist for over 20 years and is heavily involved in research, particularly in immunotherapy and targeted therapies. He led the development of tebentafusp, the first drug proven to improve survival in advanced uveal melanoma. Professor Nathan has published over 150 papers in leading medical journals and has contributed to numerous medical textbooks. He is the Chair of the UK Uveal Melanoma Guidelines group and the UK Lead for Uveal Melanoma at the International Rare Cancer Initiative. He also leads melanoma systemic therapies for the European cancer organization's (EORTC) melanoma group.